Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Liver Cancer
Nexavar Approved for Liver Cancer in China
August 11th, 2008
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the first and only oral targeted therapy to significantly improve overall survival in patients with the disease. The approval was based on two international Phase 3 double-blind, placebo-controlled trials that evaluated more than 800 patients who received no prior systemic therapy. "China has the highest number of liver cancer patients...
Source: Clinical Trials Week (2008-08-11)
|
